Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
search results for:
dealforma
Search
Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more
3 weeks ago
Weekly
China’s biotech market is staging a comeback that US biotech can only wish for
3 weeks ago
Deals
China
As the XBI suffers, Q1 shows a few comforting signs of underlying stability
4 weeks ago
Bioregnum
The top 100 biotech investors; FDA vaccine meeting canceled; Can Bill Anderson save Bayer?; and more
2 months ago
Weekly
Where the money is: The top 100 venture investors in biotech
2 months ago
Financing
Bioregnum
A mixed year for deals and dollars left biotech execs hungry for a better 2025
3 months ago
Deals
Bioregnum
Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale
6 months ago
Financing
Startups
Bluebird's slow sickle cell launch forces rework of loan, putting cash runway at risk
9 months ago
Pharma
Cell/Gene Tx
Merck returns to lucrative eye disease market in up to $3B deal for EyeBio
11 months ago
Startups
Deals
Vertex's $4.9B bet; Layoffs at Novartis, Genentech, Sanofi; Star founders unveil new startups; and more
Last year
Weekly
Big comeback? The Q1 report on biotech is in, and there’s been some sputtering
Last year
Financing
Deals
US-China tensions persist; Genmab's $1.8B ADC bet; New obesity startup in town; ALS drug withdrawal; and more
Last year
Weekly
Foreign investors fled Chinese biotech after the pandemic. They still haven’t come back
Last year
Financing
China
Boundless starts IPO spring with $100M listing for cancer small molecules
Last year
Financing
Startups
Boundless Bio seeks $88M in IPO as it runs two Ph1 cancer trials
Last year
Financing
Startups
The megaround rebound: Private biotechs rack up $100M+ financings
Last year
Financing
Startups
Novartis returns for another piece of IFM Therapeutics
Last year
Deals
Pharma
Startups raised millions to in-license drugs to China. Then the model fell apart
Last year
Deals
China
1
2
3
4
Next page
Last page
latest
Most read
Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision
2 hours ago
Pharma
FDA+
Exclusive: 17 health systems are working with Abundant Venture Partners to develop tech
3 minutes ago
Health Tech
Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team
33 minutes ago
Deals
AI
Merck KGaA will continue to add a tariff surcharge for US customers
2 hours ago
China
Pharma
see latest stream
